Just anotherannouncement on the way to something greater. I personally didn’t think therewould be any “adverse reaction” to R327 seeing that we have positive data from animaltesting and by reading back over the announcement “Positive Data for RECCE® 327 in MRSA Burns Wound Infection” 27.11.2019 It does appear well tolerated on human skin.
The question is, if R327 works better than market drugs and is also able to penetrate drug resistant bacteria. Where does that put our market cap?
Ann: Multiple Patients Dosed in Topical Phase I/II Clinical Trial, page-23
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.020(6.90%) |
Mkt cap ! $89.39M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 32.8¢ | 29.0¢ | $78.39K | 251.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 916 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 114230 | 1 |
View Market Depth
| Last trade - 15.59pm 25/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |